This article is more than 5 years old. Information may no longer be current.
Rivaroxaban linked with increased incidence of deep SSI after THA, TKA
Click Here to Manage Email Alerts
Patients who underwent total hip or knee arthroplasty and received rivaroxaban for thromboprophylaxis had a significantly increased incidence of deep surgical site infection compared with patients who had another type of thromboprophylaxis, according to results.
Researchers categorized 639 patients who underwent either total hip arthroplasty (THA) or total knee arthroplasty (TKA) into a study group, which received rivaroxaban, or into a control group that received any other form of chemical thromboprophylaxis for at least 2 weeks postoperatively. Researchers collected demographics, risk factors and illness severity scores, and considered the incidence of deep surgical site infection within 30 days postoperatively as the primary outcome.
Overall, results showed 159 patients received rivaroxaban and 480 patients received another form of chemical thromboprophylaxis. Researchers noted no statistically significant differences in demographics between the study and control groups, as well as an identical median length of hospital inpatient stay at 3 days. Smoking, the use of insulin, the use of immunosuppressive drugs or Charlson Comorbidity Index was not significantly different between the groups, according to results. Of the patients who received rivaroxaban, researchers found 2.5% experienced early deep surgical site infection with subsequent reoperation compared with 0.2% of patients in the control group. – by Casey Tingle
Disclosures: Brimmo reports no relevant financial disclosures. Please see the full study for a list of all other authors’ relevant financial disclosures.
Click Here to Manage Email Alerts